Mantle Cell Lymphoma Treatment Market By Mechanism Of Action (Bruton’s Tyrosine Kinase Blocker (Ibrutinib), Angiogenesis Inhibitor (Lenalidomide), CD20 Antigen Inhibitor (Rituximab), mTOR Protein Inhibitor (Temsirolimus), Proteasome Inhibitors (Bortezomib), Phase III Drug, Tabular Representation Of Phase II And I Drugs) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib and KTE-C19.

To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton’s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.

To understand the performance of drugs employed for the treatment of mantle cell lymphoma in the regional segments their respective major countries has been considered in the segment.

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drug for the treatment of mantle cell lymphoma we need to cater competitive landscape. Latest merger or acquisition and purchase of promising drug molecules are mentioned in the company profile section. The major players in global mantle cell lymphoma treatment market are Celgene Corporation Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.